您当前所在的位置:首页 > 产品中心 > 产品详细信息
24280-93-1 分子结构
点击图片或这里关闭

(4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoic acid

ChemBase编号:897
分子式:C17H20O6
平均质量:320.3371
单一同位素质量:320.12598836
SMILES和InChIs

SMILES:
O1Cc2c(c(O)c(c(OC)c2C)C/C=C(/CCC(=O)O)\C)C1=O
Canonical SMILES:
COc1c(C/C=C(/CCC(=O)O)\C)c(O)c2c(c1C)COC2=O
InChI:
InChI=1S/C17H20O6/c1-9(5-7-13(18)19)4-6-11-15(20)14-12(8-23-17(14)21)10(2)16(11)22-3/h4,20H,5-8H2,1-3H3,(H,18,19)/b9-4+
InChIKey:
HPNSFSBZBAHARI-RUDMXATFSA-N

引用这个纪录

CBID:897 http://www.chembase.cn/molecule-897.html

Collapse All Expand All

名称和登记号

名称和登记号

名称 登记号
IUPAC标准名
(4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoic acid
6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoic acid
IUPAC传统名
mycophenolic acid
6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoic acid
商标名
Myfortic
Melbex
别名
Mycophenolate
6-(1,3-Dihydro-7-hydroxy-5-methoxy-4-methyl-1-oxoisobenzofuran-6-yl)-4-methyl-4-hexanoic acid
6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid
NSC 129185
Mycophenolic acid
6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid
(4E)-6-(1,3-Dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoic Acid
6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoic acid
Mycophenoic acid
Mycophenolic acid
6-[4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl]-4-methyl-4-hexenoic acid
CAS号
24280-93-1
EC号
246-119-3
MDL号
MFCD00036814
Beilstein号
1295848
PubChem SID
24896987
24896854
46504559
160964360
PubChem CID
446541
CHEBI ID
168396
ATC码
L04AA06
CHEMBL
866
Chemspider ID
393865
DrugBank ID
DB01024
KEGG ID
D05096
美国药典/FDA物质标识码
HU9DX48N0T
维基百科标题
Mycophenolic_acid

理论计算性质

理论计算性质

JChem ALOGPS 2.1
Acid pKa 3.574788  质子受体
质子供体 LogD (pH = 5.5) 1.6079037 
LogD (pH = 7.4) 0.17404361  Log P 3.5275974 
摩尔折射率 85.2334 cm3 极化性 32.124084 Å3
极化表面积 93.06 Å2 可自由旋转的化学键
里宾斯基五规则 true 
Log P 2.36  LOG S -3.96 
溶解度 3.55e-02 g/l 

分子性质

分子性质

理化性质 安全信息 药理学性质 产品相关信息 生物活性(PubChem)
溶解度
DMSO expand 查看数据来源
Ethanol expand 查看数据来源
Insoluble expand 查看数据来源
Methanol expand 查看数据来源
methanol: soluble50 mg/mL expand 查看数据来源
methanol: soluble50 mg/mL, clear, colorless to faintly yellow expand 查看数据来源
外观
powder expand 查看数据来源
White to Off-White Solid expand 查看数据来源
熔点
136-137°C expand 查看数据来源
141°C expand 查看数据来源
疏水性(logP)
2.8 expand 查看数据来源
3.441 expand 查看数据来源
保存条件
-20°C expand 查看数据来源
-20°C Freezer expand 查看数据来源
2-8°C expand 查看数据来源
RTECS编号
MP8050000 expand 查看数据来源
欧盟危险性物质标志
环境危害性(Nature polluting) 环境危害性(Nature polluting) (N) expand 查看数据来源
有毒(Toxic) 有毒(Toxic) (T) expand 查看数据来源
有害性(Harmful) 有害性(Harmful) (Xn) expand 查看数据来源
MSDS下载
下载链接 expand 查看数据来源
下载链接 expand 查看数据来源
下载链接 expand 查看数据来源
德国WGK号
3 expand 查看数据来源
危险公开号
61-22-48/25-50/53-68 expand 查看数据来源
R:22 expand 查看数据来源
安全公开号
53-22-45-61 expand 查看数据来源
S:36/37/39 expand 查看数据来源
GHS危险品标识
GHS07 expand 查看数据来源
GHS08 expand 查看数据来源
GHS09 expand 查看数据来源
GHS警示词
Danger expand 查看数据来源
GHS危险声明
H302-H341-H360D-H372-H410 expand 查看数据来源
GHS警示性声明
P201-P273-P281-P308 + P313-P501 expand 查看数据来源
个人保护装置
Eyeshields, Faceshields, full-face particle respirator type N100 (US), Gloves, respirator cartridge type N100 (US), type P1 (EN143) respirator filter, type P3 (EN 143) respirator cartridges expand 查看数据来源
保存温度
2-8°C expand 查看数据来源
给药途径
Oral, IV expand 查看数据来源
生物利用度
94% (mofetil), 72% (sodium) expand 查看数据来源
排泄
Renal 93% expand 查看数据来源
半衰期
16–18 hours expand 查看数据来源
代谢
Hepatic expand 查看数据来源
蛋白结合率
97% expand 查看数据来源
法定药品分级
S4 (Au), POM (UK), ?-only (U.S.) expand 查看数据来源
妊娠期药物分类
D (Au), D (U.S.) expand 查看数据来源
美国(FDA)药品许可证
mycophenol expand 查看数据来源
欧盟(EMEA)药品许可证
Cellcept expand 查看数据来源
相关基因信息
human ... IMPDH1(3614), IMPDH2(3615) expand 查看数据来源
作用器官
Immune system expand 查看数据来源
纯度
≥98% expand 查看数据来源
≥98.0% (HPLC) expand 查看数据来源
95% expand 查看数据来源
98% expand 查看数据来源
成盐信息
Free Base expand 查看数据来源
质检报告
下载链接 expand 查看数据来源
下载链接 expand 查看数据来源
适用性
suitable for cell culture expand 查看数据来源
产品质量级别
PREMIUM expand 查看数据来源
Empirical Formula (Hill Notation)
C17H20O6 expand 查看数据来源

详细说明

详细说明

MP Biomedicals MP Biomedicals DrugBank DrugBank Selleck Chemicals Selleck Chemicals Wikipedia Wikipedia Sigma Aldrich Sigma Aldrich TRC TRC
MP Biomedicals -  02194172 external link
From Penicillium brevi compactum
Purity: 98%
DrugBank -  DB01024 external link
Item Information
Drug Groups approved
Description Mycophenolic acid is an an immunosuppresant drug and potent anti-proliferative, and can be used in place of the older anti-proliferative azathioprine. It is usually used as part of triple therapy including a calcineurin inhibitor (ciclosporin or tacrolimus) and prednisolone. It is also useful in research for the selection of animal cells that express the E. coli gene coding for XGPRT (xanthine guanine phosphoribosyltransferase).
Indication For the prophylaxis of organ rejection in patients receiving allogeneic renal transplants, administered in combination with cyclosporine and corticosteroids.
Pharmacology Mycophenolic acid is an antibiotic substance derived from Penicillium stoloniferum. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase. Mycophenolic acid is important because of its selective effects on the immune system. It prevents the proliferation of T-cells, lymphocytes, and the formation of antibodies from B-cells. It also may inhibit recruitment of leukocytes to inflammatory sites.
Toxicity Oral (LD50): Acute: 352 mg/kg [Rat], 1000 mg/kg [Mouse], and >6000 mg/kg [Rabbit]. Possible signs and symptoms of acute overdose could include the following: hematological abnormalities such as leukopenia and neutropenia, and gastrointestinal symptoms such as abdominal pain, diarrhea, nausea and vomiting, and dyspepsia.
Affected Organisms
Humans and other mammals
Biotransformation Mycophenolic acid is metabolized mainly by glucuronyl transferase to glucuronidated metabolites, predominantly the phenolic glucuronide, mycophenolic acid glucuronide (MPAG). MPAG does not manifest pharmacological activity. The acyl glucuronide minor metabolite has pharmacological activity similar to mycophenolic acid. The AUC ratio of Mycophenolic acid:MPAG:acyl glucuronide is approximately 1:24:0.28 at steady state.
Absorption Bioavailability following oral administration of Myfortic delayed-release tablet ranges from 70-95%
Half Life The mean elimination half-life for mycophenolic acid ranges from 8-16 hours, while that of the MPAG metabolite ranges from 13-17 hours.
Protein Binding >98%
Distribution * 54 ± 25 L
Clearance * 140 +/- 30 mL/min [Stable renal transplant patients]
References
Woodroffe R, Yao GL, Meads C, Bayliss S, Ready A, Raftery J, Taylor RS: Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study. Health Technol Assess. 2005 May;9(21):1-179, iii-iv. [Pubmed]
External Links
Wikipedia
Drugs.com
Selleck Chemicals -  S2487 external link
Research Area: Immunology
Biological Activity:
Mycophenolic acid (mycophenolate) is an immunosuppressant agent used to prevent rejection in organ transplantation. Mycophenolic acid (mycophenolate) is derived from the fungus Penicillium stoloniferum. Mycophenolate mofetil is metabolised in the liver to the active moiety mycophenolic acid. Mycophenolic acid (mycophenolate) inhibits inosine monophosphate dehydrogenase, the enzyme that controls the rate of synthesis of guanine monophosphate in the de novo pathway of purine synthesis used in the proliferation of B and T lymphocytes. [1] Mycophenolic acid (mycophenolate) is potent and can be used in place of the older anti-proliferative azathioprine. Mycophenolic acid (mycophenolate) is usually used as part of a three-compound regimen of immunosuppressants, also including a calcineurin inhibitor (ciclosporin or tacrolimus) and prednisolone. [2]
Sigma Aldrich -  M3536 external link
Application
Recommended for use as a selection agent at 25 μg/ml.
Used to select animal cells expressing the Escherichia coli gene for xanthine-guanine phosphosribosyl transferase.
Biochem/physiol Actions
Immunosuppressive agent. Suppresses cytokine-induced nitric oxide production.
Immunosuppressive agent. Used to inhibit early stage biosynthesis of purine nucleotides. Used as a specific inhibitor of inosine 5′-monophosphate (IMP) dehydrogenase (IMPDH) and inducer of IMP dehydrogenase gene expression.
Protocols & Applications
Antibiotic Selector for application, solubility, solution stability, working concentration, and mode of action information
Sigma Aldrich -  M5255 external link
Application
Used to select animal cells expressing the Escherichia coli gene for xanthine-guanine phosphosribosyl transferase.
Biochem/physiol Actions
Immunosuppressive agent. Suppresses cytokine-induced nitric oxide production.
Protocols & Applications
Antibiotic Selector for application, solubility, solution stability, working concentration, and mode of action information
Sigma Aldrich -  70018 external link
Application
Used to select animal cells expressing the Escherichia coli gene for xanthine-guanine phosphosribosyl transferase.
Biochem/physiol Actions
Immunosuppressive agent. Suppresses cytokine-induced nitric oxide production.
Other Notes
Antibiotic substance. Inhibits IMP dehydrogenase1
Toronto Research Chemicals -  M831500 external link
An antibiotic produced by Penicillium brevi-compactum, P. Stoloniferum and related spp. A selective inhibitor of lymphocyte proliferation by blocking inosine monophosphate dehydrogenase, an enzyme involved in the de novo synthesis of purine nucleotides.

参考文献

参考文献

供应商提供 Google Scholar IconGoogle Scholar PubMed iconPubMed Google Books IconGoogle Books
  • Woodroffe R, Yao GL, Meads C, Bayliss S, Ready A, Raftery J, Taylor RS: Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study. Health Technol Assess. 2005 May;9(21):1-179, iii-iv. Pubmed
  • Ransom JT et al. Ther Drug Monit. 1995 Dec;17(6)
  • Senda, M., et al.: Transplantation, 60, 1143 (1995)
  • Nimmesgern, E., et al.: J. Biol. Chem., 271, 19421 (1995)
  • Gummert, J.F., et al.: J. Pharmacol. Exp. Ther., 291, 1100 (1995)
正在搜索,请耐心等待...(如果遇到网页错误或者长时间没有结果,请刷新页面[F5])

专利

专利

PubChem iconPubChem Patent Google Patent Search IconGoogle Patent

互联网资源

互联网资源

百度图标百度 google iconGoogle